75 results
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (NHL) and GLPG5201 in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
congress 2024
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic … CD19 CAR T-Cell Therapy (GLPG5201) in Relapsed/Refractory Chronic Lymphocytic Leukemia Including Richter Transformation: Results from the Phase 1
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
achievements in 2023 Corporate and Operational Performance 2023 Oncology portfolio GLPG5201 (CD19 CAR-T) in relapsed/refractory chronic lymphocytic … in development as of the date of the publication of this report: NHL, myeloma; non- Hodgkin SLE, systemic lymphoma; lupus erythematosus; CLL, chronic
6-K
EX-99.1
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
) in relapsed/refractory chronic lymphocytic leukemia (rrCLL) and Richter transformation (RT) (cut-off date: 6 September 2023)Patient recruitment of the Phase 1
6-K
EX-99.1
aka7wb0660 2ryduegfg
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
uuo8kp 6qs5o3
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
gf41p3tmslzyatr081y
12 Dec 23
Current report (foreign)
6:00am
6-K
EX-99.1
hplqwm
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.1
o8gc9bwxnegq0e1o
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.2
5k97jvdp3nns
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
mwposobsj21nwlfrn
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
f9ifodgv5qis 35
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
gjwezjfk4i8a vwick
23 May 23
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
7:30am
6-K
EX-99.1
uvnvzkpza93ybn
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
6g0mt6pf hdklce0hxo
2 May 23
Current report (foreign)
4:15pm
6-K
EX-99.1
7lrdf1o r80hw
14 Nov 22
Current report (foreign)
6:05am
6-K
EX-99.1
fgm4 wydfb1stuf
9 Nov 22
Current report (foreign)
4:05pm
6-K
EX-99.1
g3a02su2lfy wpv7m3
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
b6cj0pt89vpzo21oi5uo
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am